• 1
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 50: 733.
  • 2
    Boffetta P, Parkin DM. Cancer in developing countries. CA Cancer J Clin 1994; 44: 8l90.
  • 3
    Lorincz AT, Lancaster WD, Kumman RJ, et al. Characterization of human papillomaviruses in cervical neoplasia and their detection in routine clinical screening PetroR, zur HausenH, (eds): Viral etiology of cervical cancer. Cold Spring Harbor, NY. Cold Spring Harbor Laboratory, 1986; 225.
  • 4
    zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184: 913.
  • 5
    Coggin JR, Zur Hausen H. Workshop on papillomaviruses and cancer. Cancer Res 1979; 39: 545546.
  • 6
    Herrero R, Brinton LA, Reeves WC, et al. Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high risk population. Cancer 1990; 65: 380386.
  • 7
    Clarke EA, Morgan RW, Newman AM. Smoking as a risk factor in cancer of the cervix: Additional evidence from a case-control study. Am J Epidemiol 1982; 115: 5966.
  • 8
    Brinton LA, Hamman RF, Huggins GR, et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst 1987; 79: 2330.
  • 9
    Brinton LA, Reeves WC, Brenes MM, et al. Oral contraceptive use and risk of invasive cervical cancer. Int J Epidemiol 1990; 19: 411.
  • 10
    Hildesheim A, Reeves WC, Brinton LA, et al. Association of oral contraceptive use and human papillomaviruses in invasive cervical cancers. Int J Cancer 1990; 45: 860864.
  • 11
    Beral V, Hannaford P, Kay C. Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners' Oral Contraception Study. Lancet 1988; 2: 13311335.
  • 12
    Chen Y, Huang LH, Chen TM. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun 1996; 224: 651659.
  • 13
    Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 1996; 93: 29302935.
  • 14
    Michelin D, Gissmann L, Street D, et al. Regulation of human papillomavirus type 18 in vivo: Effects of estrogen and progesterone in transgenic mice. Gynecol Oncol 1997; 66: 202208.
  • 15
    Schon H, Grgurin M, Szekeres T, et al. A new mode of treatment of human papilloma virus associated anogenital lesions using a nonsteroid estrogen analogue.Wien Klin Wochenschr 1996; 108: 4547.
  • 16
    Brinton LA, Schairer C, Haenszel W, et al. Cigarette smoking and invasive cervical cancer. JAMA 1986; 255: 32653269.
  • 17
    Clarke EA, Morgan RW, Newman AM. Smoking as a risk factor in cancer of the cervix: Additional evidence from a case-control study. Am J Epidemiol 1982; 115: 5966.
  • 18
    La Vecchia C, Franceschi S, Decarli A, et al. Cigarette smoking and the risk of cervical neoplasia. Am J Epidemiol 1986; 123: 22.
  • 19
    Slattery ML, Robinson LM, Schuman KL, et al. Cigarette smoking and exposure to passive smoke are risk factors for cervical cancer. JAMA 1989; 261: 1593.
  • 20
    Burger MM, Hollema H. Gouw AH, et al. Cigarette smoking and human papillomavirus in patients with reported cervical cytological abnormality. Br Med J 1993; 306: 749.
  • 21
    Schiffman MH, Haley NJ, Felton JS, et al. Biochemical epidemiology of cervical neoplasia: measuring cigarette smoke constituents in the cervix. Cancer Res 1987; 47: 3886.
  • 22
    Prokopczyk B, Cox JE, Hoffman D, et al. Identification of tobacco-specific carcinogens in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst 1997; 89: 868873.
  • 23
    Ries LAG, Eisner MP, Kosary CL, et al (eds). SEER Cancer Statistics Review, 1973–1997. National Cancer Institute, Bethesda, MD, 2000.
  • 24
    Hopkins MP, Morely GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991; 77; 912917.
  • 25
    Schwartz SM, Weiss NS. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol 1986; 124: 10451047.
  • 26
    Ursin G, Peters RK, Henderson BE, et al. Oral contraceptive use and adenocarcinoma of cervix. Lancet 1994; 344: 13901394.
  • 27
    Howley P. Papillomavirinae: The viruses and their replication, in: FieldsBN, KnipeDM, and Howley, et al (eds): Fields Virology, ed 3. Philadelphia, Lippincott-Raven Publishers, 1996.
  • 28
    Kholer M, Janz I, Wintzer HO, et al. The expression of EGF receptors, EGF-like factors, and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res 1989; 9: 15371548.
  • 29
    Mitra AB, Murty VV, Pratap M, et al. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994; 54: 637639.
  • 30
    Willis G, Jennings B, Ball RY, et al. Analysis of ras point mutations and human papilloma virus 16 and 18 in cervical carcinomata and their metastases. Gynecol Oncol 1993; 49: 359364.
  • 31
    Bedell MA, Jones KH, Laimins LA. The E6-E7 region of human papillomavirus type 18 is aufficient for transformation of NIH 3T3 and rat -1 cells. J Virol 1987; 61: 36353640.
  • 32
    Chesters PM, Vousden KH, Edmonds C, et al. Analysis of HPV 16 open reading frame E7 immortalizing function in rat embryo fibroblast cells. J Gen Virol 1990; 71: 449453.
  • 33
    Madrigal M, Janicek MF, Sevin BU, et al. In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecologic Oncology 1997; 64: 1825.
  • 34
    Choo KB, Pan CC, Han SH. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 1987; 161: 259261.
  • 35
    Scheffner M, Huibregtse JM, Vierstra RD, et al. The HPV16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495505.
  • 36
    Chellappan S, Kraus VB, Kroger B, et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between the transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci U S A 1992; 89: 45494553.
  • 37
    Lane DP. Cancer, p53, guardian of the genome. Nature 1992; 358: 1516.
  • 38
    Cobrinik D, Dowdy SF, Hinds PW, et al. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 1992; 17: 312315.
  • 39
    Nevins JR. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424429.
  • 40
    Barbosa MS, Edwards C, Fisher C, et al. The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 1990; 9: 153160.
  • 41
    Heck DV, Yee Cl, Howely PM, et al. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992; 89: 44424446.
  • 42
    Higgins GD, Davy M, Roder D, et al. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet 1991; 338: 910913.
  • 43
    Munoz N, Bosch FX, de SanJose S, et al. The causal link between human papillomavirus and invasive cervical cancer: A population based case-control study in Colombia and Spain. Int J Cancer 1992; 52: 743749.
  • 44
    Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996; 88: 13611368.
  • 45
    Gostout BS, Podratz KC, McGovern RM, et al. HLA Association with Cervix Cancer in Indian Women. Abstract Presented at the Twenty-Fourth Annual Meeting of the Western Association of Gynecologic Oncologists, May 29-June 2, 1996. Gynecol Oncol 1996; 62: 415.
  • 46
    Allen M, Lalantari M, Ylitalo N, et al. HLA DQ-DR haplotype and susceptibility to cervical Carcinomal indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 1996; 48: 3237.
  • 47
    Ellis JM, Keating PJ, Baird J, et al. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1995; 1: 464470.
  • 48
    Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17): 119.
  • 49
    Kaplan LD. Human immunodeficiency virus-associated neoplasia: Changing spectrum? J Clin Oncol 1995; 13: 26842687.
  • 50
    Rezza G, Giuliani M, Branca M, et al. Determinants of squamous intraepithelial lesions (SIL) on Pap smear: the role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS Collaborative Study Group. Eur J Epidemiol 1997; 13: 937943.
  • 51
    Rellihan MA, Dooley DP, Burke TW, et al. Rapidly progressing cervical cancer in a patient with immunodeficiency virus infection. Gynecol Oncol 1990; 36: 435438.
  • 52
    Schwartz LB, Carcangiu ML, Bradham L, et al. Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: clinical opinion. Gynecol Oncol 1991; 41: 255258.
  • 53
    Shingleton HM, Patrick RL Johnston WW, et al. The current status of the Papanicolaou smear. CA Cancer J Clin 1995; 45: 305320.
  • 54
    Kurman RJ, Henson DE, Herbst AL, et al. Interim Guidelines for Management of Abnormal Cervical Cytology. The 1992 National Cancer Institute Workshop. JAMA 1994; 271: 18661869.
  • 55
    National Cancer Institute Workshop. The 1988 Bethesda System for Reporting Cervical/Vaginal Cytological Diagnoses. JAMA 1989; 262: 931934.
  • 56
    Duggan M. Cytologic and histologic diagnosis and significance of controversial squamous lesions of the uterine cervix. Mod Pathol 2000; 13: 252260.
  • 57
    Sherman ME, Kelly D. High Grade squamous intraepithelial lesions and invasive carcinoma following the report of three negative papinicolaou smears: Screening failures or rapid progression? Mod Pathol 1992; 5: 337342.
  • 58
    Robb JA. The “ASCUS” swamp. Diagn Cytopathol 1994; 11: 319320.
  • 59
    Frable J. Litigation cells: Definition and observations on a cell type in cervical vaginal smears not addressed by the Bethesda System. 1994;11:213.
  • 60
    Borst M, Butterworth CE, Baker V, et al. Human papillomavirus screening for women with atypical Papinicolaou smears. J Reprod Med. 1991; 36: 9599.
  • 61
    Syrjanen K, Mantylarvi R, Saarikoski S, et al. Factors associated with progression of cervical human papillomavirus (HPV) infections into carcinoma in situ during a long-term prospective follow-up. Br J Obstet Gynaecol 1988; 95: 10961102.
  • 62
    Reid R, Lorincz A. New generation of human papillomavirus tests, in RubinSC and HoskinsWJ (eds): Cervical Cancer and Preinvasive Neplasia, Philadelphia, Lippincott Williams & Wilkins Publishers, 1996.
  • 63
    Cox JT, Lorincz AT, Schiffman MH, et al. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous-cells of undetermined significance. Am J Obstet Gynecol 1995; 172: 946954.
  • 64
    Colgan TJ, Patten SF, Lee JJ. A clinical trial of the AutoPap 300 QC System for quality control of cervicovaginal cytology in the clinical laboratory. Acta Cytol 1995; 39: 11911198.
  • 65
    Ashfaq R, Liang Y, Saboorian MH. Evaluation of PAPNET™ system for rescreening of negative smears. Diagn Cytopathol 1995; 13: 3136.
  • 66
    Hutchinson ML. Assessing the costs and benefits of alternative rescreening strategies. Acta Cytol 1996; 40: 48.
  • 67
    Bishop JW, Bigner SH, Colgan TJ, et al. Multicenter masked evaluation of AutoCyte PREP thin layers with matched conventional smears. Including initial biopsy results. Acta Cytol 1998; 42: 189197
  • 68
    Ferenczy A, Franco E, Arseneau J, et al. Diagnostic performance of Hybrid Capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study. Am J Obstet Gynecol 1996; 175(3 Pt 1): 651656.
  • 69
    Medical Practice and Ethics Committee, Management of Gynecologic Cancers, in Society of Gynecologic Oncologists Clinical Practice Guidelines. Chicago: Society of Gynecologic Oncologists, 1996, pp. 3443.
  • 70
    Bandy LC, Clarke-Pearson DL, Silverman PM, et al. Computed tomography in evaluation of extrapelvic lymphadenopathy in carcinoma of the cervix. Obstet Gynecol 1985; 65: 7376.
  • 71
    Villasanta U, Whitley NO, Haney PJ, Brenner D. Computed tomography in invasive carcinoma of the cevix: An appraisal. Obstet Gynecol 1983; 62: 218224.
  • 72
    Rose PG, Adler LP, Rodriguez M, et al. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999; 17: 4145.
  • 73
    Creasman WT. New gynecologic cancer staging. Gynecol Oncol 1995; 58: 157158.
  • 74
    Averette HE, Donato DM, Lovecchio JL, et al. Surgical staging of gynecologic malignancies. Cancer 1987; 60: 20102020.
  • 75
    Averette HE, Dudan RC, Ford JH, Jr. Exploratory celiotomy for surgical staging of cervical cancer. Am J Obstet Gynecol 1972; 113: 10901096.
  • 76
    Committee of Nomenclature: Society of Gynecologic Oncologists Staging Manual 1994.
  • 77
    van Nagell JR, Donaldson ES, Wood EG, et al. The significance of vascular invasion and lymphatic infiltration in invasive cervical cancer. Cancer 1978; 41: 228234.
  • 78
    Sevin BU, Nadji M, Averette HE, et al. Microinvasive carcinoma of the cervix. Cancer 1992; 70: 21212128.
  • 79
    Morris M, Mitchell MF, Silva EG, et al. Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix. Gynecol Oncol 1993; 51: 193196.
  • 80
    National Institutes of Health Consensus Development Conference statement on cervical cancer. Gynecol Oncol. 1997 Sep; 66: 351361
  • 81
    Nasu I, Meurer W, Fu YS. Endocervical glandular atypia and adenocarcinoma. A correlation of cytology and histology. Int J Gynecol Pathol 1993; 12: 208218.
  • 82
    Zweizig S, Noller K, Reale F, et al. Neoplasia associated with atypical glandular cells of undetermined significance on cervical cytology. Gynecol Oncol 1997; 65: 314318.
  • 83
    Wolf JK, Levenback C, Malpica A, et al. Adenocarcinoma in situ of the cervix: Significance of cone biopsy margins. Obstet Gynecol 1996; 88: 8286.
  • 84
    Shin CH, Schorge JO, Lee KR, Sheets EE. Conservative management of adenocarcinoma in situ of the cervix. Gynecol Oncol 2000: 79: 610.
  • 85
    Averette HE, Nguyen HN, Donato DM, et al. Radical hysterectomy for invasive cervical cancer. A 25-year prospective experience with the Miami technique. Cancer 1993; 71: 14221437.
  • 86
    van Nagell JR, Maruyama Y, Donaldson, et al. Phase II clinical trial using californium-252 fast neutron brachytherapy, external pelvic radiation and extrafascial hysterectomy in the treatment of bulky, barrel-shaped stage IB cervical cancers. Cancer 1986; 57: 19181922.
  • 87
    van Nagell JR, Donaldson ES, Parker JC, et al. The prognostic significance of cell type and lesion size in patients with cervical cancer treated by radical surgery. Gynecol Oncol 1977; 5: 142151.
  • 88
    Perez CA, Camal H M, Kao MS, et al. Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of Stage IB and IIA a carcinoma of the uterine cervix: Final report. Gynecol Oncol 1987; 27: 129140.
  • 89
    Lagasse LD, Creasman WT, Shingleton HM, et al. Results and complications of operative staging in cervical cancer experience of the Gynecologic Oncology Group. Gynecol Oncol 1980; 9: 9098.
  • 90
    LaPolla JP, Schlaerth JB, Gaddis JO, et al. The influence of surgical staging on the evaluation and treatment of patients with cervieal carcinoma. Gynecol Oncol 1986; 24: 194206.
  • 91
    Rubin SC, Brookland R, Mikuta JJ, et al. Para-aortic nodal metastases in early cervical carcinoma: Long-term survival following extended-field radiotherapy. Gynecol Oncol 1984; 18: 213217.
  • 92
    Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535540.
  • 93
    Curtin JP, Hoskins WJ, Venkatraman ES, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): A randomized phase III trial. Gynecol Oncol 1996; 61: 310.
  • 94
    Sedlis A, Bundy BN, Rotman M, et al. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999 May; 73: 177183.
  • 95
    Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 13391348.
  • 96
    Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 11371143.
  • 97
    Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 11441153.
  • 98
    Peters WA 3d, Liu PY, Barrett RJ 2d, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 16061613.
  • 99
    Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 11541161.
  • 100
    Bricker EM, Butcher HR Jr, et al. Surgical treatment of advanced and recurrent cancer of the pelvic viscera: An evaluation of 10 years' experience. Ann Surg 1960; 152: 388402.
  • 101
    Brunschwig A. Complete excision of the pelvic viscera for advanced carcinoma. Cancer 1948; 1: 177.
  • 102
    Coleman R, Keeney ED, Freedman RS, et al. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 1994; 55: 2935.
  • 103
    Averette HE, Lichtinger M, Sevin BU, et al. Pelvic exenteration: A 15-year experience in a general metropolitan hospital. Am J Obstet Gynecol 1984; 150: 179184.
  • 104
    Penalver MA, Bejany DE Averette HE, et al. Continent urinary diversion in gynecologic oncology. Gynecol Oncol 1989; 34: 274288.
  • 105
    Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 1999; 17: 26762680.
  • 106
    Sporn MB, Roberts AB. Cervical cancer regression induced by all-trans-retinoic acid. J Natl Cancer Inst1994: 86; 476477.
  • 107
    Meyskens FL Jr, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 1994; 86: 539543.
  • 108
    Mitchell MF, Hittelman WN, Lotan R, et al. Chemoprevention trials in the cervix: Design, feasibility, and recruitment. J Cell Biochem Suppl 1995; 23: 104112.
  • 109
    Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papilloma virus 16-transformed cells. Eur. J. Immunol 1993; 23: 22422249.
  • 110
    Donnelly JJ, Martinez D, Jansen KU, et al. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996; 173: 314320.
  • 111
    Rose RC, Lane C, Wislon S, et al. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 1999; 17: 21292135.
  • 112
    Zhang LF, Zhou J, Chen S, et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18: 10511058.
  • 113
    Gurski KJ, Steller MA. Progress and prospects in vaccine therapy for gynecologic cancers. Oncology 1997; 11; 17271734.
  • 114
    Borysiewicz LK, Flanders A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347; 15231527.
  • 115
    Ezzell C. Cancer “vaccines;” An idea whose time has come? J NIH Res 1995; 7: 4649.
  • 116
    Blachere NE, Li Z, Chandawarkar RY, et al. Heat shock protein-peptide complexes reconstituted in vitro elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997; 186: 13151322.
  • 117
    Srivastava P. Peptide-binding heat shock proteins in the endoplasmic reticulum: Role in immune response to cancer and in antigen presentation. Adv Cancer Res 1993; 62; 153177.
  • 118
    Schoell WM, Mirhashemi R, Liu B, et al. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: An approach to immunotherapy of cervical cancer. Gynecol Oncol 1999; 74: 448455.
  • 119
    Alexander M, Salgaller ML, Celis E, et al. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996; 175: 15861593.
  • 120
    Cheever MA, Chen W. Therapy with cultured T cells: Principles revisted. Immunol Rev 1997: 157: 177194.
  • 121
    Chen L, Mizuno MT, Singhal MC, et al. Induction of ctyotoxic T cell lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992; 148: 26172621.
  • 122
    Evans C, Bauer S, Grubert T, et al. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother 1996; 42: 151160.
  • 123
    Ressing ME, vanDriel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope. Cancer Res 1996; 5: 582588.